Two recent appellate decisions reached different outcomes in NEC baby formula litigation, highlighting how appeals continue to shape lawsuits involving Abbott, Mead Johnson, and claims that cow's milk-based formula increased the risk of necrotizing enterocolitis in premature infants.
A new Georgia Supreme Court decision could influence medical malpractice and wrongful death litigation for years by reaffirming important jury trial protections and limiting how damages caps apply.
The FDA has expanded Dupixent's use to additional pediatric patients while continuing to review reports of cutaneous T-cell lymphoma. Researchers, regulators, and attorneys are closely watching developments involving the widely prescribed medication.
The appellate ruling rejected key defense arguments from Abbott Laboratories and could influence future NEC baby formula lawsuits involving premature infants and cow’s milk-based formula products.
A recent Illinois NEC baby formula verdict is adding to ongoing litigation involving claims that certain preterm formulas increased the risk of NEC in premature infants.
As NEC baby formula lawsuits grow nationwide, families in Georgia and beyond are seeking answers about whether feeding decisions contributed to devastating diagnoses in premature infants.
Traffic crashes killed more people than homicides in metro Atlanta in 2024, according to new data from transportation safety advocates. Pedestrians and cyclists face growing risks as outdated street design and infrastructure gaps continue to contribute to preventable deaths.
A Georgia woman filed a federal lawsuit alleging the eczema drug Dupixent may be linked to cutaneous T-cell lymphoma (CTCL). The complaint raises concerns about risk warnings and delays in diagnosis.
The FDA has approved an update to Depo-Provera’s U.S. warning label as lawsuits alleging a link between the birth control shot and brain tumors continue to grow. Here’s what the label change means for ongoing litigation.
A new JAMA study reveals that many Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis survivors face long-term physical, emotional, and social challenges after leaving the hospital, often without adequate support or guidance for recovery.